89 results on '"Lorusso D."'
Search Results
2. 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
3. 617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study.
4. First line ovarian cancer treatment: Scanning the horizon
5. LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
6. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
7. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
8. PARPi related toxicities: do we need more appropriate instruments to evaluate it?
9. Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study.
10. 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer.
11. 524MO Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel.
12. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC).
13. Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women.
14. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
15. Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer.
16. 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician's choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
17. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775).
18. How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?
19. Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center.
20. 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
21. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
22. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors.
23. LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study.
24. LBA34 ENGOT-ov48/EUDARIO: European trial on enhanced DNA repair inhibition in ovarian cancer.
25. Chemotherapy-free treatments: are we ready for prime time?
26. Neoadjuvant chemotherapy-related leukopoenia as a biomarkers predicting survival outcomes in locally advanced cervical cancer.
27. Immunotherapy and epithelial ovarian cancer: a double-edged sword?
28. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
29. 419 - Incorporating Minimally Invasive Nerve-Sparing Radical Hysterectomy for Locally-Advanced Cervical Cancer.
30. 152 - Sentinel Node Detection in Endometrial Cancer: A Single Center Experience Over 200 Cases of Hysteroscopic Injection of Tracers.
31. 150 - Oncologic Effectiveness and Safety of Nerve-Sparing Radical Hysterectomy in Cervical Cancer.
32. 7 - A Prospective Study on the Risk of Occult Malignancies and 30-Day Morbidity in Women Undergoing Miniamlly Invasive Risk-Reducing Surgery.
33. 151 - Assessing the Risk of Pelvic and Para-Aortic Nodal Involvement in Apparent Early-Stage Ovarian Cancer Undergoing Retroperitoneal Staging.
34. Laparoscopic Mapping in Endometrial Cancer Following Hysteroscopic Injection of Indocyanine Green.
35. P.13.10 NON-ELECTIVE SURGERY FOR ACUTE COMPLICATED DIVERTICULITIS. PRIMARY RESECTION-ANASTOMOSIS OR HARTMANN'S PROCEDURE? A SYSTEMATIC REVIEW AND META-ANALYSIS.
36. 715 POSTER Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors.
37. 755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H).
38. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
39. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
40. A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings.
41. LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012.
42. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC).
43. 795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors.
44. 1585P Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023).
45. 749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study.
46. 748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma.
47. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
48. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
49. 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
50. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.